ArticleOncoscience2015

RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

Mariana Petaccia de Macedo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.